Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen

被引:52
作者
Bos, Rinke [1 ]
van Duikeren, Suzanne [1 ]
Morreau, Hans [3 ]
Franken, Kees [1 ]
Schumacher, Ton N. M. [4 ]
Haanen, John B. [4 ]
van der Burg, Sjoerd H. [2 ]
Melief, Cornelis J. M. [1 ]
Offringa, Rienk [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Tumor Immunol Grp, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands
[4] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1158/0008-5472.CAN-08-1864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinoembryonic antigen (CEA) is intensively studied as a potential target for immunotherapy of colorectal cancers. Although overexpressed by tumors, CEA is also expressed in normal tissues, raising questions about the feasibility and safety of CEA-targeted immunotherapy. We investigated these issues in transgenic mice in which the expression of human CEA in normal tissues closely resembles that in man. Our data show that the T-cell response against CEA in these mice is blunted by both thymic and peripheral tolerance. Consequently, effective tumor targeting is only achieved by adoptive transfer of T cells from nontolerant donors in combination with interventions that eliminate peripheral immune regulatory mechanisms. However, such treatments can result in severe intestinal autoimmune pathology associated with weight loss and mortality. Interestingly, preconditioning of recipient mice by depletion of T-regulatory cells results in immune-mediated tumor control in the absence of toxicity. In this setting, CEA-specific T-cell responses are lower than those induced by toxic regimens and accompanied by additional T-cell responses against non-self antigen. These findings illustrate the importance of testing adoptive immunotherapies targeting self antigens such as CEA in preclinical in vivo models and show that the choice of immune intervention regimen critically determines the balance between therapeutic efficacy and toxicity. [Cancer Res 2008;68(20):8446-55]
引用
收藏
页码:8446 / 8455
页数:10
相关论文
共 48 条
[1]   CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells [J].
Adler, AJ ;
Marsh, DW ;
Yochum, GS ;
Guzzo, JL ;
Nigam, A ;
Nelson, WG ;
Pardoll, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (10) :1555-1564
[2]  
Aranda R, 1997, J IMMUNOL, V158, P3464
[3]   Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice:: Control by CD4+ regulatory T cells and IL-10 [J].
Asseman, C ;
Read, S ;
Powrie, F .
JOURNAL OF IMMUNOLOGY, 2003, 171 (02) :971-978
[4]   Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+T-cell repertoire [J].
Bos, R ;
van Duikeren, S ;
van Hall, T ;
Kaaijk, P ;
Taubert, R ;
Kyewski, B ;
Klein, L ;
Melief, CJM ;
Offringa, R .
CANCER RESEARCH, 2005, 65 (14) :6443-6449
[5]   Characterization of antigen-specific immune responses induced by Canarypox virus Vaccines [J].
Bos, Rinke ;
Van Duikeren, Suzanne ;
Van Hall, Thorbald ;
Lauwen, Marjolein M. ;
Parrington, Mark ;
Berinstein, Neil L. ;
McNeil, Bryan ;
Melief, Cornelis J. M. ;
Verbeek, J. Sjef ;
Van der Burg, Sjoerd H. ;
Offringa, Rienk .
JOURNAL OF IMMUNOLOGY, 2007, 179 (09) :6115-6122
[6]  
Clarke P, 1998, CANCER RES, V58, P1469
[7]   Paraneoplastic syndromes affecting the nervous system [J].
Darnell, Robert B. ;
Posner, Jerome B. .
SEMINARS IN ONCOLOGY, 2006, 33 (03) :270-298
[8]  
EADESPERNER AM, 1994, CANCER RES, V54, P4169
[9]   DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection [J].
Facciabene, A ;
Aurisicchio, L ;
Elia, L ;
Palombo, F ;
Mennuni, C ;
Ciliberto, G ;
La Monica, N .
HUMAN GENE THERAPY, 2006, 17 (01) :81-92
[10]   High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens [J].
Germeau, C ;
Ma, WB ;
Schiavetti, F ;
Lurquin, C ;
Henry, E ;
Vigneron, N ;
Brasseur, F ;
Lethé, B ;
De Plaen, E ;
Velu, T ;
Boon, T ;
Coulie, PG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02) :241-248